LY404187

LY404187

CAT N°: 28741
Price:

From 165.00 140.25

LY404187 is a benzothiadiazide positive allosteric modulator of AMPA receptors.{46485} It increases glutamate-induced activation of GluR1i, -2i, -2o, -3i, and -4i subunit-containing AMPA receptors with EC50 values of 5.65, 0.15, 1.44, 1.66, and 0.21 µM, respectively, in a calcium influx assay. LY404187 is selective for these AMPA receptors over GluR6 subunit-containing kainate receptors at 10 µM. LY404187 increases currents induced by glutamate and AMPA in rat prefrontal cortex pyramidal neurons (EC50s = 1.3 and 1.2 µM, respectively) but not in AMPA-stimulated primary rat embryonic hippocampal or primary cerebellar Purkinje neurons.{46486,46487} LY404187 prevents decreases in the number of dopaminergic neurons in the substantia nigra induced by MPTP and 6-OHDA (Item No. 25330) in mouse and rat, respectively, models of Parkinson’s disease when administered at a dose of 0.5 mg/kg per day.{46488}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-[2-(4?-cyano[1,1?-biphenyl]-4-yl)propyl]-2-propanesulfonamide
  • Correlated keywords
    • LY-404187 R1i GluR-1i GluR1-i -2 o -3 -4 GluR-6 Glu-R6 6OHDA
  • Product Overview:
    LY404187 is a benzothiadiazide positive allosteric modulator of AMPA receptors.{46485} It increases glutamate-induced activation of GluR1i, -2i, -2o, -3i, and -4i subunit-containing AMPA receptors with EC50 values of 5.65, 0.15, 1.44, 1.66, and 0.21 µM, respectively, in a calcium influx assay. LY404187 is selective for these AMPA receptors over GluR6 subunit-containing kainate receptors at 10 µM. LY404187 increases currents induced by glutamate and AMPA in rat prefrontal cortex pyramidal neurons (EC50s = 1.3 and 1.2 µM, respectively) but not in AMPA-stimulated primary rat embryonic hippocampal or primary cerebellar Purkinje neurons.{46486,46487} LY404187 prevents decreases in the number of dopaminergic neurons in the substantia nigra induced by MPTP and 6-OHDA (Item No. 25330) in mouse and rat, respectively, models of Parkinson’s disease when administered at a dose of 0.5 mg/kg per day.{46488}

We also advise you